For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Recursion Pharmaceuticals Inc’s stock clocked out at $7.60, up 3.40% from its previous closing price of $7.35. In other words, the price has increased by $3.40 from its previous closing price. On the day, 3.95 million shares were traded. RXRX stock price reached its highest trading level at $7.79 during the session, while it also had its lowest trading level at $7.205.
Ratios:
To gain a deeper understanding of RXRX’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.70 and its Current Ratio is at 4.70. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Morgan Stanley on May 22, 2023, initiated with a Equal-Weight rating and assigned the stock a target price of $8.
On March 16, 2023, Needham started tracking the stock assigning a Buy rating and target price of $17.
On September 16, 2022, KeyBanc Capital Markets started tracking the stock assigning a Overweight rating and target price of $20.KeyBanc Capital Markets initiated its Overweight rating on September 16, 2022, with a $20 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Apr 17 ’24 when Secora Michael sold 23,124 shares for $7.58 per share. The transaction valued at 175,349 led to the insider holds 1,231,055 shares of the business.
Secora Michael sold 25,000 shares of RXRX for $191,658 on Apr 16 ’24. The Chief Financial Officer now owns 1,216,679 shares after completing the transaction at $7.67 per share. On Apr 16 ’24, another insider, Borgeson Blake, who serves as the Director of the company, sold 11,447 shares for $7.66 each. As a result, the insider received 87,725 and left with 7,229,861 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RXRX now has a Market Capitalization of 1783362688 and an Enterprise Value of 1442471808. For the stock, the TTM Price-to-Sale (P/S) ratio is 36.79 while its Price-to-Book (P/B) ratio in mrq is 3.83. Its current Enterprise Value per Revenue stands at 32.361 whereas that against EBITDA is -4.429.
Stock Price History:
The Beta on a monthly basis for RXRX is 0.87, which has changed by 0.47001934 over the last 52 weeks, in comparison to a change of 0.23061275 over the same period for the S&P500. Over the past 52 weeks, RXRX has reached a high of $16.75, while it has fallen to a 52-week low of $4.54. The 50-Day Moving Average of the stock is -28.76%, while the 200-Day Moving Average is calculated to be -18.66%.
Shares Statistics:
It appears that RXRX traded 6.28M shares on average per day over the past three months and 3617760 shares per day over the past ten days. A total of 226.26M shares are outstanding, with a floating share count of 146.66M. Insiders hold about 32.05% of the company’s shares, while institutions hold 82.87% stake in the company. Shares short for RXRX as of 1711584000 were 39761938 with a Short Ratio of 6.33, compared to 1709164800 on 42815751. Therefore, it implies a Short% of Shares Outstanding of 39761938 and a Short% of Float of 25.44.
Earnings Estimates
The current assessment of Recursion Pharmaceuticals Inc (RXRX) involves the perspectives of 6 analysts closely monitoring its market dynamics.On average, analysts expect EPS of $-0.42 for the current quarter, with a high estimate of $-0.39 and a low estimate of $-0.46, while EPS last year was $-0.34. The consensus estimate for the next quarter is $-0.42, with high estimates of $-0.38 and low estimates of $-0.46.
Analysts are recommending an EPS of between $-1.49 and $-2.1 for the fiscal current year, implying an average EPS of $-1.72. EPS for the following year is $-1.86, with 8 analysts recommending between $-1.12 and $-3.5.
Revenue Estimates
In the current quarter, 6 analysts expect revenue to total $12.65M. It ranges from a high estimate of $20.8M to a low estimate of $10M. As of the current estimate, Recursion Pharmaceuticals Inc’s year-ago sales were $12.13M, an estimated increase of 4.30% from the year-ago figure. For the next quarter, 6 analysts are estimating revenue of $13.17M, an increase of 19.50% over than the figure of $4.30% in the same quarter last year. There is a high estimate of $20.8M for the next quarter, whereas the lowest estimate is $10.9M.
A total of 7 analysts have provided revenue estimates for RXRX’s current fiscal year. The highest revenue estimate was $83.3M, while the lowest revenue estimate was $43M, resulting in an average revenue estimate of $56.16M. In the same quarter a year ago, actual revenue was $44.58M, up 26.00% from the average estimate. Based on 7 analysts’ estimates, the company’s revenue will be $88.43M in the next fiscal year. The high estimate is $254.9M and the low estimate is $41.89M. The average revenue growth estimate for next year is up 57.50% from the average revenue estimate for this year.
